Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800299 | 0.88 | HSP90B1 (0.58) | NT5EADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL780400 | 0.80 | TAAR1 (0.58) | NT5E | |
| SCHEMBL23200375 | 0.80 | TAAR1 (0.58) | NT5E | |
| SCHEMBL800874 | 0.80 | TAAR1 (0.58) | NT5E | |
| SCHEMBL23200376 | 0.80 | TAAR1 (0.58) | NT5E | |
| SCHEMBL23710671 | 0.80 | TAAR1 (0.58) | NT5E | |
| SCHEMBL23710670 | 0.80 | TAAR1 (0.58) | NT5E | |
| SCHEMBL800400 | 0.80 | TAAR1 (0.58) | NT5E | |
| SCHEMBL2047557 | 0.80 | NT5E (0.65) | NT5EADORA3ADORA1ADORA2BLMNA | |
| SCHEMBL3053788 | 0.80 | NT5E (0.65) | NT5EADORA3ADORA1ADORA2BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2623104-A1 | Substituted nucleoside and nucleotide analogs | Alios Biopharma, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | NT5E 15/4885ADORA3 174/4885ADORA1 189/4885 |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | PNP, TYMP, NTPCR | NT5E 19/4885ADORA3 143/4885ADORA1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.